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systematically collected through visiting social health insurance bureau websites, 
literature review and key informant interview. Case study and comparison analy-
sis were conducted among these schemes. Results: Two kinds of risk sharing 
schemes, performance based scheme and financial based scheme, were employed 
in sampling provinces and cities, with the latter model more often implemented. 
Performance based scheme has only been developed in one city (Guangzhou) for a 
non-small-cell lung cancer drug. Patients eligible for inclusion criteria and treated 
in one of three designated hospitals could be qualified to reimburse for more than 
one year treatment if they were responsive to the drug. Other provinces and cities 
has adopted the financial based scheme, mainly focusing on increasing patients 
access to expensive drugs, usually for breast cancer, leukemia and non-small-cell 
lung cancer and not covered by health insurance schemes. For instance, local health 
insurance fund of Zhejiang and Jiangsu province would only reimburse patients’ five 
to six months treatment and pharmaceutical company should sponsor patients’ 
treatment for the next six months. Besides, cities like Qingdao and Chengdu imple-
mented the price volume scheme for special drugs and medical materials in order to 
control fund expenditure. ConClusions: By risk sharing scheme, some innovative 
drugs, previously not covered by social health insurance, can be reimbursed, which 
will increase patients’ access, reduce patients economic burden, and help expend-
ing pharmaceutical companies’ market share. However, as risk sharing scheme in 
China has only been adopted for only one or two years, long-term impact still needs 
to be observed and evaluated.
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In an increasingly resource-constrained environment, a variety of innovative 
contracting arrangements exist, representing an alternative to conventional pric-
ing and reimbursement agreements between payer and manufacturer. There are 
various tools and resources that may influence funding with which payers and 
prescribers would welcome support from manufacturers. objeCtives: To gain 
an overview of contractual agreements currently used within the pharmaceu-
tical sector and to uncover how innovative contracting has, and continues to, 
evolve. Methods: Secondary research was conducted to identify examples of 
innovative contracting, highlighting elements that work and associated hur-
dles, in order to understand issues relating to transparency and implementa-
tion. Results: Sixteen markets worldwide embrace innovative schemes with 
a further 5 markets beginning to show uptake. In the past, agreements were 
predominantly performance-based. However, companies are increasingly moving 
towards financial schemes such as product bundling, confidential discounts and 
fixed price treatments. The most common elements of risk-sharing agreements 
are price volume agreements (39%), requirement for data collection (29.5%), and 
access limited only to eligible patients (13.1%). Innovative contracts are predomi-
nantly used for drugs that relate to high cost or high performance with oncology 
being the therapeutic area that dominates these agreements. ConClusions: 
Innovative contracting schemes can aid manufacturers with market access, help 
to maintain price and increase usage. However, the current design of many agree-
ments is suboptimal, and there are hurdles which need to be overcome. It is 
important that there is a balance between risk and incentive for all stakeholders, 
and this balance between the benefits and cost implications must be carefully 
considered.
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This study critically appraises the contribution of cost-effectiveness analysis (CEA) 
in improving the rational allocation of health care resources in Ireland. While Ireland 
has successfully established some of the institutional infrastructure for CEA, there 
remain key areas for improvement: 1) Ireland has an explicit cost-effectiveness 
threshold of € 45,000/QALY. It resulted from negotiations between the pharmaceu-
tical industry and the public health service and only applies to pharmaceutical 
interventions. If Ireland is to use a threshold, it would be better served by an empiri-
cally determined threshold that applies to all interventions. 2) The threshold has 
recently been exceeded by a number of expensive drugs, in some cases by a very 
large margin. Conversely, despite being highly cost-effective, colorectal screening 
remains unimplemented due to a failure to allocate resources. In the absence of 
clarity around these decisions, the allocations appear to indicate that considera-
tions of budget impact are dominating rather than complementing those of cost-
effectiveness. 3) Recent CEAs by Ireland’s statutory health technology assessment 
authority, the Health Information and Quality Authority (HIQA), appear to confuse 
average cost-effectiveness ratios with incremental cost-effectiveness ratios (ICERs). 
Clarity around the interpretation of cost-effectiveness evidence is required to instil 
confidence in the process. 4) Ireland has an established CEA process to appraise 
new drugs. However, this process has been bypassed in recent cases, as some costly 
cancer drugs have been approved before being subject to CEA, despite recommen-
dations that these drugs be assessed. Consistency in approach is required to instil 
confidence in the process. (5) Greater transparency around reimbursement decisions 
would be desirable, whereby the relevant bodies issue documentation explaining 
their decisions and deliberations. In conclusion, CEA could make a greater contri-
bution to rational resource allocation in Ireland if more rigorous and consistent 
decision rules were applied. Greater accountability of the decision making process 
should further that goal.
data: Coverage with Evidence Development (CED). The objective of this study was 
to review the outcomes of the CEDs granted by TLV during the years 2005 to 2012, 
and to appreciate if it is an effective way to manage uncertainty. Methods: All 
decisions published from January 2005 to December 2012 on the TLV website were 
screened. All decisions that included a CED were reviewed and the information 
on the initial decision for a CED and the final decision based on the evidence 
developed were extracted in a standardized way. The information was then ana-
lyzed. Results: During the period TLV issued 38 decisions with a CED, 4 in 2012, 
5 in 2011, 11 in 2010, 3 in 2009, 2in 2008, 8 in 2007, 5 in 2006 and none in 2005. For 
10 CEDs issued 2010 to 2012 the time for evaluation had to yet been reached. For 
12 CED decision taken from 2006 to 2010 the time for evaluation was reached but 
no decision had been taken and the products continue to be reimbursed accord-
ing to the conditions in the temporary reimbursement decision. 7 products were 
granted general reimbursement and 9 limited reimbursement based on the evalu-
ation of the evidence. No product was rejected reimbursement. ConClusions: 
Although it is early to draw any final conclusions, a significant number of CED 
decisions were not followed up with a final decision, which leads to continued 
reimbursement. The risk of de-reimbursement based on a CED seems minimal in 
Sweden. Therefore it is unclear if CED will actually contribute to manage uncer-
tainty in Sweden.
PHP207
varianCeS in individualS’ PreSCriPtion drug CoStS in ireland
Walshe V.1, Kenneally M.2, Buckley G.2
1Health Service Executive, Cork, Ireland, 2University College Cork, Cork, Ireland
objeCtives: To assess the average individual’s drug costs prescribed under the 
main community drug scheme in Ireland over time, by age cohort and by geo-
graphical region. It also examined regional costs having standardized for age and 
sex. Methods: The 2002 to 2012 average pharmacy payment per eligible person, 
number of items prescribed per person and the average cost per item prescribed 
were calculated. The most recent average individual cost of medicines was exam-
ined for each of the 4 health regions and 32 sub-regions by 22 age and sex cohorts. 
Regional age and sex adjustments were made by applying the scheme’s national 
age and sex weights to each region’s costs. This produced regional cost estimates 
independent of age and sex variations. Results: Community drug expenditure 
has undergone substantial growth in the past 10 years with costs more than dou-
bling and the number of persons covered by the main scheme increasing by nearly 
60%. Nationally an individual’s average cost of medicines was € 713 in 2011, varying 
from € 670 (-6%) in HSE-West to € 762 (+7%) in HSE-South. Sub-regional LHO (local 
health office) cost variances were significantly greater ranging from € 200 to € 1,200. 
Average cost increases with age and for persons over 75 was nearly 4 times those 
aged 35 to 44 (€ 1,689 versus € 446). Removing the impact of age and sex increases 
cost variances marginally overall, restraining some regions costs and promoting 
others. ConClusions: Individuals’ prescription drug costs vary significantly by 
age and sex however regional cost differences are not explained by variances in age 
and sex and may be a result of other factors such as prevalence of chronic health 
conditions and GP prescribing patterns.
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objeCtives: To analyze and classify the Risk-Sharing Schemes (RSSs) proposed in 
reimbursement applications received by Agency for Health Technology Assessment 
in Poland (AHTAPol) in 2012. Methods: Risk-Sharing Schemes proposed in reim-
bursement applications received by AHTAPol in 2012 were quantitatively and 
qualitatively analyzed. The classification of the RSSs was also conducted based 
on both Carlson’s approach and the Polish Act on Reimbursement of medicinal 
products. Results: In the studied period, 52 reimbursement applications with 26 
proposed RSSs were received by AHTAPol. They were classified into 5 categories 
according to the Act on Reimbursement. The most common category was making 
the official sales price dependent on the applicant providing supplies at a reduced 
price, as specified in the negotiations on the price of the medicine (34.61%). Further 
categories were: making the official sales price dependent ona pay-back of a part 
of the reimbursement obtained to the entity which is obliged to finance bene-
fits with public funds (23.08%), making the official sales price dependent on the 
level of turnover of the medicine (11.54%) and making the level of the applicant’s 
revenues dependent on the health effects achieved (3.85%). RSSs classified as 
others constituted 26.92% of all. Among 26 proposed RSSs only 8 of them could be 
classified according to the Carlson’s approach (1 proposition included more than 
one category). As a results, 4 Price Volume Agreements, 4 Manufacturer Funded 
Treatment Initiation and 1 Conditional Treatment Continuationwere identi-
fied. ConClusions: Most of the propositions should not be considered as RSS 
according to the Carlson’s approach. The most common propositions were related 
to medicinal product’s price reduction and did not include any risk sharing. There 
is a strong need for further research.
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objeCtives: To understand current risk sharing scheme landscape for innova-
tive pharmaceuticals in some typical provinces and cities of China. Methods: 
Risk sharing schemes for pharmaceuticals in four provinces (Guangdong, Zhejiang, 
Jiangsu and Sichuan) and three cities (Guangzhou, Hangzhou and Chengdu) were 
